Retatrutide and gray hair: evidence review

A post on r/peptides drew attention in mid-2025 when a user reported noticing more gray hairs after starting retatrutide, the investigational triple agonist (GLP-1, GIP, glucagon) from Eli Lilly. Replies ranged from "same here" to firm skepticism. No clinical trial has reported hair graying as a named adverse event for retatrutide. But the biology is not straightforward, and several threads running through the broader GLP-1 class literature are worth examining.

This article explains what the Phase 2 and Phase 3 trial data say about retatrutide and hair, what the GLP-1 class literature reports on hair loss more broadly, what the biology of hair graying tells us about plausible mechanisms, and why the community signal is worth noting but not yet a conclusion.

What the published retatrutide trials report on hair

The Phase 2 obesity trial by Jastreboff and colleagues (NEJM, 2023) randomised 338 adults to weekly subcutaneous retatrutide at 1, 4, 8 or 12 mg, or to placebo, for 48 weeks. The paper's adverse-event table focuses on gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation) and a dose-dependent increase in heart rate. No hair-related events, including graying or alopecia, appear in the published adverse-event data^[1].

The Phase 3 TRIUMPH-1 programme enrolled 2,335 adults and reported topline results in May 2026. The TRIUMPH-1 press release highlighted gastrointestinal adverse events and a dose-dependent dysesthesia signal (skin sensitivity, 5.1% to 12.5% versus 0.9% on placebo). Hair graying or color change is not named in the topline report. Full peer-reviewed data from TRIUMPH-1 have not yet been published, so a full adverse-event breakdown is not yet available in the literature^[4].

The honest summary: no clinical trial has specifically identified gray hair as an adverse event for retatrutide. That absence does not rule it out. Phase 2 trials typically enrol a few hundred participants for less than a year, which limits statistical power to detect low-frequency or slowly developing effects. Phase 3 full publication data, when available, will provide a more complete picture.

What the GLP-1 class literature does report on hair

Hair shedding, specifically telogen effluvium, is the hair-related adverse event most consistently associated with GLP-1 receptor agonists as a class. A 2025 review by Rojas Lopez and colleagues identified telogen effluvium and androgenetic alopecia as the most frequently reported hair-loss subtypes across GLP-1 receptor agonists including semaglutide, liraglutide, tirzepatide, and dulaglutide. More than 1,000 spontaneous cases had been reported to the FDA adverse event database by the time of that review^[2]. The authors note that hair follicle cycle disruption is a plausible mechanism, though direct causal evidence remains limited.

Hair graying, as a distinct phenomenon, is not named as an adverse event in the same GLP-1 class literature. The r/peptides community report on retatrutide sits, for now, in the category of anecdotal signal without corroboration in controlled data. That does not make it implausible. Rapid weight loss of any origin can accelerate certain hair-cycle changes, and retatrutide produces some of the largest weight-loss magnitudes seen in any pharmacological obesity trial to date^[1].

The biology of hair graying and why rapid weight loss could matter

Hair graying (canities) results from a gradual decline in melanogenesis in the hair follicle. The primary driver is depletion of melanocyte stem cells (MSCs) in the hair bulge. O'Sullivan and colleagues (2021) characterise the process as starting with reduced tyrosinase activity and impaired melanosome transfer, progressing to apoptosis of pigment-producing cells, and eventually to exhaustion of the bulge MSC pool, at which stage graying becomes largely irreversible^[3]. The paper identifies oxidative stress as a major accelerant: it damages melanocyte DNA, depletes antioxidant defences including catalase, and selectively triggers melanocyte apoptosis.

Several factors associated with rapid, pharmacologically driven weight loss could interact with this biology. Caloric restriction can reduce antioxidant nutrient availability (copper, zinc, selenium, B vitamins) and tip the oxidative balance inside hair follicles. Systemic stress signals, including elevated cortisol during periods of significant metabolic change, are also implicated in MSC dysfunction in the literature. None of this is retatrutide-specific. It applies to any intervention producing fast, substantial weight loss.

The glucagon receptor component of retatrutide adds a third dimension not present in semaglutide or tirzepatide. Glucagon agonism raises energy expenditure and mobilises stored energy, contributing to the triple agonist's larger weight-loss effect. Whether glucagon receptor activation has any direct or indirect role in melanocyte biology is not established in the published literature. It is mechanistic speculation at this stage, not a tested hypothesis.

What we do not yet know

The honest accounting of gaps is substantial. We do not have a controlled adverse-event dataset from the full TRIUMPH-1 publication. We do not have long-term retatrutide data beyond the Phase 2 48-week window in terms of peer-reviewed adverse-event detail. We do not know whether any hair graying observed in community users reflects a pharmacological effect of retatrutide, a nutritional consequence of rapid weight loss, a coincidence with normal aging, or some combination of all three. The r/peptides thread is a Tier 3 signal in epidemiological terms, valuable for generating hypotheses but not for drawing conclusions.

For anyone considering retatrutide: it is investigational and not approved by the FDA, EMA, MHRA, or any national agency we track. There is no authorised consumer route to retatrutide. See the retatrutide regulatory overview for the current status by country.

What to watch for

The full peer-reviewed publication of TRIUMPH-1 will include a complete adverse-event table and may shed light on skin and hair signals at scale. Dermatology researchers tracking GLP-1 class adverse events are expanding their databases to include newer triple agonists. Community observations like the r/peptides thread are worth recording but require corroboration in controlled data before a causal claim can be made. If you notice hair changes while on any weight-loss pharmacotherapy, the right step is to discuss them with the prescribing clinician, who can assess whether nutritional deficiencies, the weight-loss process itself, or the medication is the most likely contributor.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Retatrutide is investigational and not approved for any indication. Always consult a qualified healthcare professional before using any peptide or investigational compound. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.